Abiopharma

🔍 Mehta Vimal (Director)

Company: BioXcel Therapeutics, Inc. (BTAI)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 18,000 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 39,259.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 125.00
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: By BioXcel LLC | shares_owned_after: 480,343.00 | Footnotes: F2
• Sold 18,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
• F3: On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 18,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date.